CohBar’s CEO to Participate in Upcoming BIO Webinar
29 nov. 2021 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update
15 nov. 2021 16h02 HE
|
CohBar, Inc.
Company to host conference call at 5:00 p.m. ET MENLO PARK, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria...
CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021
01 nov. 2021 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants
28 oct. 2021 08h45 HE
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
CohBar Announces Proposed Public Offering of Common Stock and Warrants
27 oct. 2021 16h01 HE
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic...
CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021
13 oct. 2021 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference
05 oct. 2021 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors
15 sept. 2021 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH)
08 sept. 2021 09h00 HE
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at Upcoming Investor Conferences
02 sept. 2021 16h05 HE
|
CohBar, Inc.
MENLO PARK, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...